Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 12/20 | 0.56 |
| ▸ | LIMK1 | P53667 | 4/20 | 0.55 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16741448 | 1.00 | MKNK1 (0.56) | MKNK1LIMK1P2RX3ALDH1A1LMNA | |
| SCHEMBL16384777 | 1.00 | MKNK1 (0.56) | MKNK1LIMK1P2RX3ALDH1A1LMNA | |
| SCHEMBL16372092 | 1.00 | MKNK1 (0.56) | MKNK1LIMK1P2RX3ALDH1A1LMNA | |
| SCHEMBL16741394 | 0.89 | LIMK1 (0.51) | MKNK1LIMK1ALDH1A1LMNA | |
| SCHEMBL15534999 | 0.89 | MKNK1 (0.54) | MKNK1LIMK1 | |
| SCHEMBL16708782 | 0.89 | MKNK1 (0.54) | MKNK1LIMK1 | |
| SCHEMBL16751173 | 0.89 | LIMK1 (0.53) | MKNK1LIMK1ALDH1A1LMNA | |
| SCHEMBL16370982 | 0.85 | LIMK1 (0.59) | MKNK1LIMK1P2RX3ALDH1A1LMNA | |
| SCHEMBL16741326 | 0.85 | LIMK1 (0.59) | MKNK1LIMK1P2RX3ALDH1A1LMNA | |
| SCHEMBL15534269 | 0.85 | LIMK1 (0.59) | MKNK1LIMK1P2RX3ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233866-B1 | PYRAZOLOPYRIDINAMINES AS MKNK1 AND MKNK2 INHIBITORS | Bayer Pharma AG (DE) | 2021-04-21 | — | — | EP | disclosed |
| US-20180162877-A1 | PYRAZOLOPYRIDINAMINES AS MKNK1 AND MKNK2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-14 | — | — | US | disclosed |
| EP-3233866-A1 | PYRAZOLOPYRIDINAMINES AS MKNK1 AND MKNK2 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2017-10-25 | — | — | EP | disclosed |
| US-9540392-B2 | Thienopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-10 | — | — | US | disclosed |
| WO-2016096721-A1 | PYRAZOLOPYRIDINAMINES AS MKNK1 AND MKNK2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | WO | disclosed |
| EP-2852595-B1 | SUBSTITUTED BENZOTHIENOPYRIMIDINES | Bayer Pharma AG (DE) | 2016-06-22 | — | — | EP | disclosed |
| EP-2852596-B1 | THIENOPYRIMIDINES | Bayer Pharma AG (DE) | 2016-06-22 | — | — | EP | disclosed |
| US-20160159789-A1 | SUBSTITUTED PYRAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-09 | — | — | US | disclosed |
| EP-3019505-A1 | SUBSTITUTED PYRAZOLO-PYRIDINAMINES | Bayer Pharma Aktiengesellschaft (DE) | 2016-05-18 | — | — | EP | disclosed |
| US-9296757-B2 | Substituted benzothienopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-29 | — | — | US | disclosed |
| US-20150152121-A1 | Substituted Benzothienopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-04 | — | — | US | disclosed |
| US-20150133425-A1 | THIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-14 | — | — | US | disclosed |
| EP-2852596-A1 | THIENOPYRIMIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2015-04-01 | — | — | EP | disclosed |
| EP-2852595-A1 | SUBSTITUTED BENZOTHIENOPYRIMIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2015-04-01 | — | — | EP | disclosed |
| WO-2015004024-A1 | SUBSTITUTED PYRAZOLO-PYRIDINAMINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-15 | — | — | WO | disclosed |
| WO-2013174735-A1 | SUBSTITUTED BENZOTHIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013174744-A1 | THIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162877-A1 | PYRAZOLOPYRIDINAMINES AS MKNK1 AND MKNK2 INHIBITORS | MKNK1, MKNK2, MAP4K5 | MKNK1 1/4885LIMK1 287/4885P2RX3 907/4885 |
| US-20150152121-A1 | Substituted Benzothienopyrimidines | CCNA1, CCNT2, TYMP | MKNK1 4342/4885LIMK1 4038/4885P2RX3 743/4885 |
| US-20150133425-A1 | THIENOPYRIMIDINES | TYMP, DPYD, TYMS | MKNK1 2721/4885LIMK1 3711/4885P2RX3 667/4885 |
| US-20160159789-A1 | SUBSTITUTED PYRAZOLOPYRIDINES | DPYD, PGF, VEGFA | MKNK1 2345/4885LIMK1 2545/4885P2RX3 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.